Simultaneous Applications Submitted to FDA and EMA for Siltuximab for ...

Janssen Research & Development, LLC announced the simultaneous submissions of a Biologic License Application to the United States Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for siltuximab for the treatment of patients with multicentric Castleman disease who are HIV-negative and human ... (more)

http://www.drugs.com/nda/siltuximab_130903.html?